Antibody-drug conjugates (ADCs) are an increasingly powerful class of cancer therapeutics that combine the targeted precision of monoclonal antibodies with the cytotoxic potency of small-molecule drugs. By directing chemotherapy agents specifically to tumor cells, ADCs aim to maximize antitumor activity while minimizing damage to healthy tissues. One key challenge in ADC design is selecting the right target and payload—features that define efficacy, safety and resistance. 

Continue reading “What Makes OBI-992 Different? A Closer Look at This TROP2 Antibody Drug Conjugate”